Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026
Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Fineline Cube Jan 27, 2026
Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Fineline Cube Jan 27, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Deals

Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round

Fineline Cube Jan 9, 2023

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark

Fineline Cube Jan 9, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485

Fineline Cube Jan 9, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...

Company Deals

VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant

Fineline Cube Jan 9, 2023

Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...

Company Drug

Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval

Fineline Cube Jan 9, 2023

Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...

Company Drug

Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study

Fineline Cube Jan 9, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...

Company Drug

Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials

Fineline Cube Jan 9, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...

Policy / Regulatory

China’s National Health Commission Releases Updated COVID-19 Treatment Plan

Fineline Cube Jan 9, 2023

The National Health Commission (NHC) has released the 10th edition of the national COVID-19 Diagnosis...

Company Drug

HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study

Fineline Cube Jan 6, 2023

On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...

Company Medical Device

Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study

Fineline Cube Jan 6, 2023

Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...

Company Drug

Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133

Fineline Cube Jan 6, 2023

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...

Company Deals

Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials

Fineline Cube Jan 6, 2023

Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...

Company Deals

Immune-Onc Therapeutics Completes $131 Million Series B Financing

Fineline Cube Jan 6, 2023

US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...

Company Drug

Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC

Fineline Cube Jan 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

Singular Medical Secures Series B+ Funding for Cardiac Device Development

Fineline Cube Jan 6, 2023

Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...

Company Drug

Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828

Fineline Cube Jan 6, 2023

German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...

Company Drug

Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review

Fineline Cube Jan 6, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data

Fineline Cube Jan 6, 2023

China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...

Company Deals

Mindray Partners with BOMImed for Exclusive Canadian Sales and Service

Fineline Cube Jan 6, 2023

China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical...

Company Deals

Simnova Partners with Orna Therapeutics for In Situ CAR Therapies

Fineline Cube Jan 6, 2023

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...

Posts pagination

1 … 525 526 527 … 614

Recent updates

  • Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
  • Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
  • HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.